Overcoming cordycepin limitations with SLNs-based nanoformulation: formulation development and cytotoxicity evaluation against human breast cancer cells
Sep 2026· Medical Oncology· Vol 43· 0 citations· 55 references
Medicine
TL;DR
Improved cellular uptake and greater drug accumulation inside cells led to improved apoptotic activity and thus, more clonogenic activity and thus, more clonogenic activity, suggesting that SLNs-based nanoencapsulation is a promising approach for enhancing the therapeutic efficacy and safety of COR for breast cancer therapy.
Skin cancer continues to pose a significant global health burden, with conventional therapeutic modalities limited by systemic toxicity, poor tumor selectivity, and the development of therapeutic resistance. Glucosinolates (GLs) and their hydrolyzed product, sulforaphane, have attracted considerable interest as chemopr...
Chandrika Chaturvedi, C. Giacomantonio, H. P. Vasantha Rupasinghe· AAPS Journal· 0 citations
An overview of the composition, structure, and physicochemical properties of emulsomes, their advantages over conventional nanocarriers, and a detailed discussion of their role in cancer treatment are provided.
Chesta Gupta, S. Chauhan, Indu Singh· Current pharmaceutical desig...· 0 citations
Tamoxifen remains a cornerstone in the treatment of estrogen receptor-positive breast cancer, yet its clinical performance is limited by poor aqueous solubility, high lipophilicity, and interindividual variability associated with CYP2D6-mediated formation of its more potent active metabolites. These challenges necessit...
Lung cancer, with its high incidence and mortality rates, urgently demands innovative therapeutic strategies to address the limitations of conventional treatments, such as nonspecific toxicity and the development of drug resistance. Plant-derived exosomes have recently emerged as promising natural nanocarriers, owing t...
Xiang Xu, Jin-Ying Gu, Jia Zhang et al.· Colloids and Surfaces B: Bio...· 0 citations
Background/Objectives: Cancer causes high premature death worldwide, with 35 million new cases expected by 2050. Multidrug resistance (MDR), driven by genetic and epigenetic changes, hampers chemotherapy. In this study, polymeric nanoparticles (NPs) were formulated with an organoselenium nucleoside analogue (AFAT-Se) t...
Bruna Fracari Do Nascimento, Bianca Costa Maia-do-Amaral, Taís Baldissera Pieta et al.· Future Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
